News & Features
|
Genentech at ASCO 2008
|
||
|
Accelerated Approval for Avastin in Breast Cancer
|
||
DNA NYSE: Quote: 70.00 | Change: 1.17 | 05.16.08 | 12:45:00
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Patient Access >>
Genentech is committed to making sure price is not a barrier to access for patients.
Awards and
Recognition >>
FORTUNE magazine has named Genentech to its "100 Best Companies to Work For" and "America's Most Admired" lists.
Postdoc Program >>
Genentech's postdoctoral program offers the chance to do cutting-edge research in an inspiring environment.

